Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz Inc.
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.
Sandoz won big earlier this year at the district court level following its submission of ANDAs referencing Genentech’s Esbriet (pirfenidone) treatments for idiopathic pulmonary fibrosis. The Roche subsidiary has failed in its attempts to secure an injunction pending appeal, while firing off on the district court for its earlier ruling.
The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.
- Generic Drugs